Full Sail Capital LLC Boosts Position in Abbott Laboratories (NYSE:ABT)

Full Sail Capital LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 2.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,022 shares of the healthcare product maker’s stock after acquiring an additional 105 shares during the period. Full Sail Capital LLC’s holdings in Abbott Laboratories were worth $455,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of ABT. Regent Peak Wealth Advisors LLC increased its position in Abbott Laboratories by 2.0% during the 4th quarter. Regent Peak Wealth Advisors LLC now owns 4,873 shares of the healthcare product maker’s stock worth $551,000 after purchasing an additional 97 shares in the last quarter. ORG Wealth Partners LLC grew its stake in Abbott Laboratories by 4.5% in the 4th quarter. ORG Wealth Partners LLC now owns 42,784 shares of the healthcare product maker’s stock worth $4,840,000 after acquiring an additional 1,828 shares during the period. Czech National Bank raised its holdings in Abbott Laboratories by 6.1% in the 4th quarter. Czech National Bank now owns 376,065 shares of the healthcare product maker’s stock valued at $42,537,000 after acquiring an additional 21,630 shares during the last quarter. Aprio Wealth Management LLC lifted its stake in shares of Abbott Laboratories by 46.9% during the 4th quarter. Aprio Wealth Management LLC now owns 5,400 shares of the healthcare product maker’s stock worth $611,000 after purchasing an additional 1,724 shares during the period. Finally, Clark & Stuart Inc acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $2,179,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.4 %

Shares of NYSE ABT opened at $133.50 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $141.23. The stock’s 50-day simple moving average is $129.80 and its 200-day simple moving average is $123.46. The firm has a market cap of $232.27 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 2.52 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.02. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. As a group, equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.77%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 30.61%.

Insider Activity at Abbott Laboratories

In related news, EVP Andrea F. Wainer sold 949 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $131,123.33. Following the sale, the executive vice president now owns 74,381 shares of the company’s stock, valued at approximately $10,277,222.77. This trade represents a 1.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Sally E. Blount sold 2,600 shares of the company’s stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the transaction, the director now owns 34,058 shares of the company’s stock, valued at approximately $4,415,960.28. The trade was a 7.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 95,278 shares of company stock valued at $12,745,859. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Bank of America upped their target price on Abbott Laboratories from $133.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, March 10th. Jefferies Financial Group increased their price target on shares of Abbott Laboratories from $135.00 to $137.00 and gave the stock a “hold” rating in a research note on Thursday, April 17th. Royal Bank of Canada boosted their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a research note on Thursday, April 17th. Piper Sandler reissued an “overweight” rating and set a $145.00 price target (up previously from $133.00) on shares of Abbott Laboratories in a research report on Thursday, April 17th. Finally, Stifel Nicolaus increased their target price on shares of Abbott Laboratories from $135.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $142.59.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.